Lipella Pharmaceuticals Announces Pricing of Initial Public Offering of Common Stock

Before deducting underwriting discount and other expenses, the gross proceeds of the offering to Lipella are estimated to be around $7 million. The gross proceeds from the offering to Lipella, before deducting underwriting discounts and other offering expenses payable by Lipella, are estimated to be approximately $7 million. The qualified independent underwriter of the offering is is is is acting as such. The final prospectus will be filed with U.S. Securities and Exchange Commission ("SEC") and can be accessed on the SEC’s website at URL. Spartan Capital Securities, LLC, Attn. 333-266397), made effective by the SEC on December 19, 2022 (the “Registration Statement”). This press release does not constitute an offer or solicitation to sell such shares. Nor shall it be sold in any state or territory in which such offer or solicitation would be illegal prior to registration or qualification according to the securities laws. Forward-looking statements may include statements that are not historical facts. These forward-looking statement include statements about the timing, expected size, and completion of Lipella's initial public offer and the anticipated commencement of trading on Nasdaq Capital Market. These risks and others relating to our product candidates and operations can be found in the Registration Statement filed with the SEC. Except as required by law, we expressly disclaim any obligation whatsoever to revise any forward-looking statements. View original content:URL.htmlSOURCE Lipella Pharmaceuticals